SINGAPORE – Lianhua Qingwen traditional Chinese medicine products, although listed as Chinese proprietary medicines in Singapore for the relief of cold and flu symptoms, are not approved by the Health Sciences Authority (HSA) to treat the Covid-19.
Claims circulating on social media and in Telegram newsgroups that the products can protect against Covid-19 are false, the HSA said on Wednesday (November 17).
“To date, there is no scientific evidence from randomized clinical trials to show that a herbal product, including Lianhua Qingwen products, can be used to prevent or treat Covid-19,” said declared authority.
He added that all herbal products formulated for colds and flu, including Chinese proprietary medicines, should only be used to manage symptoms such as headache, runny or stuffy nose, sore throat. and cough.
The HSA has said the public should not believe unsubstantiated claims or spread unfounded rumors that herbal products can be used to prevent or treat Covid-19.
“Any product that claims to treat Covid-19 must be supported by scientific evidence from controlled clinical studies which show that such a product is safe and effective against Covid-19,” he said, adding that these claims must first be evaluated and have the product registered by HSA.
If found guilty of misleading advertising for products like preventing or treating Covid-19, sellers can be sentenced to imprisonment for up to two years, fined up to 5,000. $, or both.